Zkusit zdarma
Abiomed, Inc.

Abiomed, Inc.

ABMD
Cena:
 
 
Valuace
23
Růst
78
Zdraví
89

Výsledky Q1 2023

Načítám obsah…
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients.
The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite.
It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device.
preloader

Prezentace a earnings calls Abiomed, Inc. (ABMD)

DatumNázevKvartálRok
04.08.2022ABMD Q1 2023Q12023
28.04.2022ABMD Q4 2022Q42022
03.02.2022ABMD Q3 2022Q32022
28.10.2021ABMD Q2 2022Q22022
05.08.2021ABMD Q1 2022Q12022
29.04.2021ABMD Q4 2021Q42021